Singfiller欣菲聆品牌怎么样 申请店铺

我要投票 Singfiller欣菲聆在玻尿酸行业中的票数:465 更新时间:2025-11-22
Singfiller欣菲聆是哪个国家的品牌?「Singfiller欣菲聆」是 杭州协合医疗用品有限公司 旗下著名品牌。该品牌发源于浙江,由创始人沈晶在2003期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Singfiller欣菲聆品牌出海!将品牌入驻外推网,定制Singfiller欣菲聆品牌推广信息,可以显著提高Singfiller欣菲聆产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

Singfiller欣菲聆怎么样

2002年,在富阳新登,杭州协合医疗用品有限公司迈出了属于它的第一步。至此,拉开了协合医疗十年发展的大幕。2003年协合医疗迁至富阳高桥工业园区,陆续建起万级净化车间2个、质检中心和研发中心各1个,仓库楼、宿舍楼各一幢,初步实现了由微小企业向中小型企业的过渡。

2011年协合医疗收购海纳医疗(杭州)有限公司,总投资3个亿,开始建设协合医疗下沙新基地,一期已经建成1.7万平方米的标准化厂房,2000平方米的GMP净化车间3个、4000平方米的物流中心、1000平方米的研发及质检中心,可生产各类医疗器械1200余万套,实现产能25亿人民币。截止2013年,协合医疗已拥有下沙、富阳、南昌三个生产基地,杭州、北京、上海、南昌、广州、成都、重庆、福州8个医学营销中心,北京、上海两家医学会展及培训公司,集团员工400余人,年产各类医疗械200多万套,年销售逾5亿人民币,成功实现由创业阶段向快速发展阶段的转型。

协合医疗目前有八大系列产品,每年50余种医疗器械产品销往30个省市,用户达1000余家,部分产品远销往全球40多个国家,如:意大利、俄罗斯、土耳其、法国、巴西、智利、澳大利亚、加拿大。作为以发展新型复合与智能型材料为方向的杭州协合医疗用品有限公司来说,它的坚持,正在备受认可。

协合医疗构建了与国际同步的可吸收生物材料研发平台,在防粘连、止血、微整形材料、组织工程基础材料领域已获得10余项专利,另有多项专利正在申报中。当然,除了产品的研发,严格的质量控制也是企业赖以生存的根本,协合医疗遵循“质量第一、管理优先、建和谐企业、创协合品牌”的质量方针,生产车间采用当代先进的制药工艺生产线和在线监控设备,以确保持续生产出符合国家食品药品监督管理总局(CFDA)法规要求和欧盟MDD指令的第三类医疗器械、药品注射剂产品。越来越多的荣誉,越来越多的新技术,越来越成熟的发展模式,杭州协合医疗用品有限公司正在一步步成为中国可吸收生物材料领域的领军者。

In 2002, in Xindeng, Fuyang, Hangzhou Xiehe Medical Supplies Co., Ltd. took its first step. So far, it has opened the curtain of the development of cooperative medical treatment in the past ten years. In 2003, Xiehe Medical moved to Fuyang Gaoqiao Industrial Park, successively built two 10000 level purification workshops, one quality inspection center and one R & D center, one warehouse building and one dormitory building, initially realizing the transition from small and medium-sized enterprises to small and medium-sized enterprises. In 2011, Xiehe Medical purchased Haina medical (Hangzhou) Co., Ltd. with a total investment of 300 million yuan, and started to build a new base of Xiehe Medical in Xiasha. In phase I, 17000 square meters of standardized factory buildings, 2000 square meters of GMP purification workshops, 4000 square meters of logistics centers and 1000 square meters of R & D and quality inspection centers have been built, which can produce more than 12 million sets of various medical devices and achieve a production capacity of 2.5 billion yuan RMB. As of 2013, Xiehe Medical Co., Ltd. has three production bases in Xiasha, Fuyang and Nanchang, eight medical marketing centers in Hangzhou, Beijing, Shanghai, Nanchang, Guangzhou, Chengdu, Chongqing and Fuzhou, two medical exhibition and training companies in Beijing and Shanghai, with more than 400 employees, an annual production of more than 2 million sets of various medical devices, and an annual sales of more than 500 million yuan. It has successfully realized the transformation from the entrepreneurial stage to the fast stage Transformation of rapid development stage. At present, Xiehe Medical has eight series of products, more than 50 kinds of medical device products are sold to 30 provinces and cities every year, with more than 1000 users. Some products are exported to more than 40 countries around the world, such as Italy, Russia, Turkey, France, Brazil, Chile, Australia and Canada. Hangzhou Xiehe Medical Supplies Co., Ltd., which aims to develop new composite and intelligent materials, is being recognized for its persistence. Synergetic medical has built an internationally synchronized research and development platform for absorbable biomaterials. It has obtained more than 10 patents in the fields of anti adhesion, hemostasis, micro plastic materials and basic materials for tissue engineering, and many other patents are under application. Of course, in addition to product research and development, strict quality control is also the foundation for the survival of enterprises. Xiehe Medical follows the quality policy of "quality first, management first, building a harmonious enterprise and creating Xiehe brand". The production workshop adopts the modern advanced pharmaceutical process production line and on-line monitoring equipment to ensure the continuous production in line with the State Food and Drug Administration (CFDA) Class III medical devices and drug injection products required by regulations and EU MDD directives. With more and more honors, more and more new technologies and more mature development models, Hangzhou Xiehe Medical Supplies Co., Ltd. is becoming the leader in the field of absorbable biomaterials in China step by step.

本文链接: https://brand.waitui.com/8f8f64f88.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

澳大利亚将禁止机舱内使用充电宝

澳大利亚几家主要航空公司21日宣布,将于下月开始陆续禁止在航班上使用充电宝或为充电宝充电,以降低机舱内火灾风险。这些安全措施将适用于所有国内和国际航班,且不会给予任何豁免。据澳大利亚广播公司21日报道,澳洲航空公司及其旗下的澳航支线、捷星航空宣布将于12月15日起实施禁令,而维珍澳大利亚航空公司的禁令将从12月1日起执行。(财联社)

11分钟前

峰飞航空:累计获得eVTOL确认订单300架

11月22日消息,峰飞航空累计获得eVTOL商业订单2000架,其中,截至2025年底的确认订单是300架。(证券时报)

11分钟前

兆威机电、迈威生物港股IPO获中国证监会备案

11月22日消息,中国证监会国际合作司发布关于深圳市兆威机电股份有限公司、迈威(上海)生物科技股份有限公司境外发行上市备案通知书,兆威机电拟发行不超过69,058,450股境外上市普通股并在香港联合交易所上市。迈威生物拟发行不超过62,664,600股境外上市普通股并在香港联合交易所上市。(金十数据APP)

11分钟前

阿斯利康宣布投资20亿美元扩建马里兰州生产基地

当地时间11月21日,阿斯利康宣布计划投资20亿美元,用于扩建其位于马里兰州的长期生产基地。此项投资将为该州创造2600个就业岗位,包括保留当地现有职位、建筑活动相关岗位,以及新增300个高技能职位。(界面新闻)

11分钟前

我国卫星物联网业务商用试验正式启动

11月22日,在2025中国“5G+”工业互联网大会上,工业和信息化部对外宣布,我国卫星物联网业务商用试验正式启动。此次商用试验期为两年。目标通过开展商用试验,丰富卫星通信市场供给,激发市场主体活力,提升行业服务能力,建立安全监管体系,形成可复制可推广的经验和模式,支撑商业航天、低空经济等新兴产业安全健康发展,服务构建新发展格局。(第一财经)

11分钟前

本页详细列出关于Singfiller欣菲聆的品牌信息,含品牌所属公司介绍,Singfiller欣菲聆所处行业的品牌地位及优势。
咨询